Cite

HARVARD Citation

    Kraynyak, K. et al. (2022). SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial. Journal of infectious diseases. pp. 1923-1932. [Online]. 
  
Back to record